Compare Hinge Health Inc. Class A Common Stock (HNGE) vs IQVIA Holdings Inc. Common Stock (IQV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs IQVIA Holdings Inc. Common Stock — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while IQVIA Holdings Inc. Common Stock trades at $261.7 (market cap $42.91B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 5.1× Hinge Health Inc. Class A Common Stock's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, IQVIA Holdings Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and IQVIA Holdings Inc. Common Stock for 6 Days on average.
| HNGE | IQV | |
|---|---|---|
Market Cap | $8.48B | $42.91B |
Volume | 879,799 | 1,333,456 |
Sector | Health | Health |
52-Week High | $105.14 | $275.02 |
52-Week Low | $31.17 | $156.66 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.10B | $57.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
IQVIA Holdings (IQV) trades at $260.71, down 0.57% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $284.64. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.15 surpassing the $3.03 estimate. Revenue growth is steady, projected at $17.0B for 2026, while profitability metrics like a 23.01% ROE and 8.1% net income margin reflect operational strength. The company continues to innovate, launching new predictive analytics tools for life sciences clients.
The outlook for IQV remains positive, supported by strong earnings performance and analyst optimism, though investors should note valuation multiples above sector averages and debt levels. Key risks include competitive pressures in clinical research services and macroeconomic sensitivity affecting client spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About IQVIA Holdings Inc. Common Stock
IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →
